Entry Detail



General Information

Database ID:exR0270321
RNA Name:hsa-miR-654-3p
RNA Type:miRNA
Chromosome:chr14
Starnd:+
Coordinate:
Start Site(bp):101040269End Site(bp):101040290
External Links:hsa-miR-654-3p



Disease Information

Disease Name:Multiple Sclerosis
Disease Category:Nervous System Diseases
MeSH ID:D009103
Type:Diseases Category/Nervous System Diseases
Alias:Sclerosis, Multiple//Sclerosis, Disseminated//Disseminated Sclerosis//MS (Multiple Sclerosis)//Multiple Sclerosis, Acute Fulminating



Expression Detail

GEO ID:GSE140106
Description:Serum exosome microRNAs predict multiple sclerosis disease activity after fingolimod treatment
Experimental Design:Fingolimod treatment
Case Disease Type:Multiple Sclerosis
Case Disease SubType:NA
Case Sample:Fingolimod treated Multiple Sclerosis
Control Sample:Untreated
Number of Case:27
Number of Control:27
Number of Samples:54





Regulatory Relationship

mRNA targets:
Gene SymbolChromosomeStart Site(bp)End Site(bp)Strand
ANKRD49
chr11
94493979
94499578
+
ATAD1
chr10
87751512
87841343
-
CAMTA1
chr1
6785454
7769706
+
CLN8
chr8
1755778
1801711
+
EPB41L1
chr20
36091504
36232799
+
RAB10
chr2
26034084
26137454
+
RNF220
chr1
44405194
44651724
+
miRNA targets:NA
circRNA targets:
circRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
hsa_circ_0001146
chr20
34241449
34246936
-
lncRNA targets:
lncRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
AC005899.4
chr17
32328441
32329395
+
AC079781.5
chr7
97851688
97972985
-
AL049795.2
chr1
32170733
32176568
+
AL358472.3
chr1
153966516
153966930
+
HCG11
chr6
26521709
26527404
+
MCM3AP-AS1
chr21
46229196
46259390
+
NEAT1
chr11
65422774
65445540
+
SNHG1
chr11
62851984
62855953
-
THUMPD3-AS1
chr3
9349689
9398579
-
TUG1
chr22
30969245
30979395
+
XIST
chrX
73820649
73852723
-
ZFAS1
chr20
49278178
49299600
+
Display:



Experiment Detail

GEO ID:GSE140106
Sample Source:Blood
Source Fraction:Exosome
Platform:GPL11154
Method:NGS
Num of detected RNA Type:1
Num of detected RNAs of this Type:1907
Sample treatment protocol:Exosomes were isolated from 1 mL RNase A (37 °C for 10 min; 100 ng/ml; Qiagen, Australia) treated serum, by size exclusion chromatography (qEV iZONE Science).
RNA Extract protocol:Serum exosomes were processed for RNA extraction using the Plasma/Serum Circulating & Exosomal RNA Purification Mini Kit (Norgen Biotek, Cat. 51000) according to the manufacturer's protocol.
RNA library preparation protocol:Exosome RNA sequencing libraries were then constructed using the NEBNext Multiplex Small RNA Library Prep Kit for Illumina (BioLabs, New England) according to the manufacturer's instructions.



Reference

PMID:31721043
Title:Serum Exosome MicroRNAs Predict Multiple Sclerosis Disease Activity after Fingolimod Treatment
Author:Ebrahimkhani S, Beadnall HN, Wang C, Suter CM, Barnett MH, Buckland ME, Vafaee F
Journal:Mol Neurobiol. 2020 Feb;57(2):1245-1258.
Description:we sought the possible utility of serum exosome microRNAs as biomarkers for disease activity in multiple sclerosis patients in response to fingolimod therapy.